NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
05/31/2022
Back to search
Official data from USPTO
ADIPOGEN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
62
Latest update
05/31/2022
Trademark type
Word
Nice classes
1, 5
Filing date
12/19/2008
Registration date
05/22/2012
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/31/2022
Last transaction
05/31/2022
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
11/01/2009
First use in commerce
11/01/2009
Drawing code
4
Owner type
03
Owner location
SAN DIEGO, CA
Examiner
CARL III,FRED
Law office
L80
Current location
GENERIC WEB UPDATE
Holders and representatives
Holders
ADIPOGEN LIFE SCIENCES, INC.
ADIPOGEN INTERNATIONAL, INC.
A. I. (pessoa física)
A. I. (pessoa física)
Representatives
Rob G. Leach Charmasson, Buchaca & Leach, LLP
Technical classification
Nice Classes
Class 1Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Assays for research purposes; Biochemical proteinsenzymes and antibodies for scientific and medical research; Biochemical reagents commonly known as probesfor detecting and analyzing molecules in protein or nucleotide arrays; Biochemicalspolypeptides for in vitro research use; Biochemicalspolyclonal and monoclonal antibodies for in vitro scientific or research use; Biomedical compoundspeptide substrates used in analyzing and detecting enzymes and proteins for laboratory or research use; Chemicals for use in the purification of proteins for in vitro use; Diagnostic kits for research and in vitro use consisting primarily of polyclonal and monoclonal antibodiesbuffersreagents to monitor proteins and reagents; Diagnosticsdiagnostic preparations and reagents other than for medical or veterinary purposes; Diagnostic preparations and reagents for scientific or research use; Diagnostic preparations and reagents for clinical or medical laboratory use; Diagnostic reagents for in vitro use in biochemistryclinical chemistry and microbiology; Laboratory chemicalsan antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; Protein arrays and nucleotide arrays for scientific and medical research; Reagent for chemical analyses; Reagents for scientific or medical research use; Reagents for use in scientific apparatus for chemical or biological analysis; Stem cells and stem cell reagents for research purposes; Testing kits containing peptide substrates used in analyzing and detecting proteinsenzymes and receptors for laboratory or research use; Testing kits containing peptide substrates used in analyzing and detecting proteinsenzymes and receptors for clinical or medical laboratory use
Class 5
Biological preparations for medical purposes; Chemical reagents for medical or veterinary purposes; Diagnostic agentspreparations and substances for medical purposes; Diagnostic kits consisting primarily of polyclonal and monoclonal antibodiesbuffersreagents for use in disease testing; Diagnostic preparations for medical purposes; Diagnostic reagents for medicinal use; Drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; Medical diagnostic reagents; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary systemfor the treatment of obesity and diabetes and inflammatory disordersfor use in angiogenesisdermatologyoncologyhematology and in tissue and organ transplantationin ophthalmology and for gastroenterological disorders ; Pharmaceutical preparations and substances for the treatment of infectious diseasesblood disorderspaininflammationsepsisalopeciaobesity and cognitive disorders; Pharmaceutical preparations and natural medicinal extracts derived from animalplant and microorganism sources for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctionobesity and diabetesoncologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Reagents and media for medical and veterinary diagnostic purposes
Publications
History of USPTO decisions and trademark events.
62 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
05/31/2022
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
05/31/2022
E89R
TEAS SECTION 8 & 9 RECEIVED
05/26/2022
PUM1
OFFICE ACTION ISSUED POU1
09/09/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/09/2021
E89R
TEAS SECTION 8 & 9 RECEIVED
08/24/2021
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
05/22/2021
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
05/24/2018
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
05/24/2018
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/24/2018
E815
TEAS SECTION 8 & 15 RECEIVED
05/10/2018
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
08/09/2017
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
05/22/2017
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
02/12/2014
R.PR
REGISTERED-PRINCIPAL REGISTER
05/22/2012
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
04/17/2012
REGV
LAW OFFICE REGISTRATION REVIEW COMPLETED
04/16/2012
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
04/13/2012
SUPC
STATEMENT OF USE PROCESSING COMPLETE
03/30/2012
IUAF
USE AMENDMENT FILED
03/28/2012
EISU
TEAS STATEMENT OF USE RECEIVED
03/28/2012
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/20/2011
EX4G
SOU EXTENSION 4 GRANTED
10/19/2011
EXT4
SOU EXTENSION 4 FILED
10/05/2011
EEXT
SOU TEAS EXTENSION RECEIVED
10/05/2011
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/02/2011
EX3G
SOU EXTENSION 3 GRANTED
04/01/2011
EXT3
SOU EXTENSION 3 FILED
03/28/2011
EEXT
SOU TEAS EXTENSION RECEIVED
03/28/2011
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/13/2010
DOCK
ASSIGNED TO EXAMINER
10/13/2010
EX2G
SOU EXTENSION 2 GRANTED
10/12/2010
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/12/2010
EXT2
SOU EXTENSION 2 FILED
09/24/2010
EEXT
SOU TEAS EXTENSION RECEIVED
09/24/2010
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/07/2010
EX1G
SOU EXTENSION 1 GRANTED
04/05/2010
EXT1
SOU EXTENSION 1 FILED
04/05/2010
EEXT
SOU TEAS EXTENSION RECEIVED
04/05/2010
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/04/2009
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
12/04/2009
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/09/2009
NOAM
NOA MAILED - SOU REQUIRED FROM APPLICANT
10/06/2009
PUBO
PUBLISHED FOR OPPOSITION
07/14/2009
NPUB
NOTICE OF PUBLICATION
06/24/2009
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
06/09/2009
ALIE
ASSIGNED TO LIE
06/09/2009
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/07/2009
XAEC
EXAMINER'S AMENDMENT ENTERED
06/07/2009
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/07/2009
GNEA
EXAMINERS AMENDMENT E-MAILED
06/07/2009
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/07/2009
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/07/2009
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/07/2009
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/07/2009
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/22/2009
GNRT
NON-FINAL ACTION E-MAILED
03/22/2009
CNRT
NON-FINAL ACTION WRITTEN
03/22/2009
DOCK
ASSIGNED TO EXAMINER
03/14/2009
MPMK
NOTICE OF PSEUDO MARK MAILED
12/24/2008
NWAP
NEW APPLICATION ENTERED
12/23/2008
Continuous trademark protection
Get notified about every new filing that threatens ADIPOGEN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.